StocksFundsScreenerSectorsWatchlists
CLOV

CLOV - Clover Health Investments, Corp. Stock Price, Fair Value and News

0.80USD+0.01 (+1.27%)Delayed as of 28 Mar 2024, 11:09 am ET

Market Summary

CLOV
USD0.80+0.01
Delayedas of 28 Mar 2024, 11:09 am
1.27%

CLOV Alerts

  • 1 major insider buys recently.
  • Big fall in Revenue (Y/Y)
  • Losses in recent quarter

CLOV Stock Price

View Fullscreen

CLOV RSI Chart

CLOV Valuation

Market Cap

379.8M

Price/Earnings (Trailing)

-1.78

Price/Sales (Trailing)

0.19

Price/Free Cashflow

-3.26

CLOV Price/Sales (Trailing)

CLOV Profitability

Return on Equity

-74.5%

Return on Assets

-37.39%

Free Cashflow Yield

-30.66%

CLOV Fundamentals

CLOV Revenue

Revenue (TTM)

2.0B

Rev. Growth (Yr)

-43.23%

Rev. Growth (Qtr)

5.85%

CLOV Earnings

Earnings (TTM)

-213.4M

Earnings Growth (Yr)

15.61%

Earnings Growth (Qtr)

-69.94%

Breaking Down CLOV Revenue

52 Week Range

0.711.63
(Low)(High)

Last 7 days

2.5%

Last 30 days

-17.2%

Last 90 days

-18%

Trailing 12 Months

-12.5%

How does CLOV drawdown profile look like?

CLOV Financial Health

Current Ratio

1.64

CLOV Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

-0.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.1B2.8B2.4B2.0B
20222.1B2.6B3.0B3.5B
2021707.7M948.1M1.2B1.5B
2020514.9M567.6M620.2M672.9M
2019000462.3M

Tracking the Latest Insider Buys and Sells of Clover Health Investments, Corp.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
soares karen
sold (taxes)
-4,134
0.8
-5,168
general counsel & secretary
Mar 15, 2024
reynoso jamie l.
sold (taxes)
-4,302
0.8
-5,378
ceo, medicare advantage
Mar 14, 2024
reynoso jamie l.
sold (taxes)
-5,677
0.73
-7,777
ceo, medicare advantage
Mar 14, 2024
wai conrad
sold (taxes)
-54,309
0.73
-74,396
chief technology officer
Mar 14, 2024
loengard anna u
bought
9,946
0.73
13,625
-
Mar 14, 2024
loengard anna u
bought
100,010
0.73
137,000
-
Feb 14, 2024
soares karen
sold (taxes)
-5,719
0.95
-6,020
general counsel & secretary
Feb 09, 2024
sharp aric r
sold (taxes)
-8,431
1.02
-8,266
ceo of value based care
Feb 08, 2024
toy andrew
sold (taxes)
-85,367
1.00
-85,367
chief executive officer
Jan 25, 2024
leffler scott j.
sold (taxes)
-81,867
0.98
-83,538
chief financial officer

1–10 of 50

Which funds bought or sold CLOV recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
unchanged
-
-654,165
4,865,350
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-20.87
-10,041,100
23,166,200
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
95.77
443,641
1,054,850
-%
Feb 23, 2024
Chicago Partners Investment Group LLC
sold off
-100
-15,693
-
-%
Feb 16, 2024
O'Dell Group, LLC
new
-
58.00
58.00
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-10.00
71.00
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-9.4
-60,000
240,000
0.02%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-34,588
257,466
-%
Feb 15, 2024
BARCLAYS PLC
added
738
450,000
520,000
-%
Feb 15, 2024
State of Wyoming
added
35.78
61,196
371,889
0.07%

1–10 of 37

Are Funds Buying or Selling CLOV?

Are funds buying CLOV calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CLOV
No. of Funds

Unveiling Clover Health Investments, Corp.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.09%
24,331,680
SC 13G/A
Jul 07, 2023
blackrock inc.
2.0%
7,772,104
SC 13G/A
Feb 09, 2023
vanguard group inc
8.38%
32,158,748
SC 13G/A
Feb 03, 2023
blackrock inc.
7.1%
27,124,981
SC 13G
Oct 04, 2022
chachacha spac c, llc
4.99%
19,132,693
SC 13D/A
Mar 10, 2022
greenoaks capital partners llc
1.3%
5,073,790
SC 13G/A
Feb 09, 2022
vanguard group inc
7.83%
25,887,351
SC 13G/A
Feb 12, 2021
integrated core strategies (us) llc
0.0%
12,933
SC 13G/A
Feb 09, 2021
greenoaks capital partners llc
40.2%
96,331,338
SC 13G
Feb 04, 2021
linden capital l.p.
0.1%
70,365
SC 13G/A

Recent SEC filings of Clover Health Investments, Corp.

View All Filings
Date Filed Form Type Document
Mar 19, 2024
4
Insider Trading
Mar 19, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 14, 2024
10-K
Annual Report
Mar 12, 2024
8-K
Current Report
Feb 15, 2024
4
Insider Trading
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Clover Health Investments, Corp.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
454.6B
371.6B
-6.04% 4.38%
20.31
1.22
14.64% 11.24%
106.2B
195.3B
3.13% 30.55%
19.78
0.54
8.17% -20.79%
100.0B
357.8B
1.79% 0.39%
11.97
0.28
10.95% 93.52%
87.7B
65.0B
6.93% 30.56%
16.74
1.35
7.86% -7.11%
41.9B
154.0B
-2.30% 15.93%
15.51
0.27
6.54% 124.79%
12.6B
14.3B
11.30% 47.77%
17.56
0.88
6.59% 6.24%
12.0B
12.1B
9.73% 82.98%
17.36
0.99
4.57% 23.40%
MID-CAP
9.7B
2.3B
11.19% 28.50%
35.74
4.3
6.06% 9.17%
7.2B
2.9B
-7.72% 12.77%
-333.68
2.47
12.20% -107.93%
2.3B
3.8B
3.63% -32.94%
11.05
0.61
-27.73% -52.50%
2.3B
1.4B
3.04% 7.42%
37.6
1.65
21.19% 34.42%
SMALL-CAP
1.7B
1.1B
9.76% -2.01%
26.93
1.59
11.31% 35.83%
1.2B
3.0B
4.38% 103.39%
-6.6
0.41
6.74% 20.73%
56.3M
-
28.14% -20.98%
-3.85
-
- -12.94%
16.9M
20.7M
-2.22% -14.90%
83.48
0.82
6.53% -85.60%

Clover Health Investments, Corp. News

Latest updates
MarketBeat • 22 Mar 2024 • 11:55 am
Yahoo Finance • 20 Mar 2024 • 10:24 am
TradingView • 12 Mar 2024 • 08:43 pm
Seeking Alpha • 12 Mar 2024 • 07:00 am
Simply Wall St • 06 Mar 2024 • 08:00 am

Clover Health Investments, Corp. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Revenue5.8%510,251482,066513,628527,775898,791856,817846,700874,379432,036427,163412,472200,325166,233169,069172,081165,505-
Gross Profit-1.3%62,26663,10776,67455,2855,14617,018-12,08612,657--9,162-46,031------
Operating Expenses10.0%575,911523,535542,435600,3811,005,411930,913949,427961,860618,825576,416594,334319,413233,862190,687148,911192,135-
  S&GA Expenses8.0%45,08041,74742,43359,21555,34847,83247,04057,69755,17745,84645,64638,61841,03229,84721,46828,483-
Interest Expenses---7.00-1364043904034034041,2111,17510,4309,2688,4777,815-
Net Income-69.9%-70,472-41,469-28,814-72,606-83,503-75,489-104,362-75,490-187,201-34,527-317,611-48,417-126,39112,7585,403-28,162-17.63
Net Income Margin-12.2%-0.10*-0.09*-0.09*-0.11*-0.10*-0.15*-0.16*-0.29*-0.40*-0.44*-0.51*-0.22*-0.20*-0.02*-0.64*-0.71*-0.79*
Free Cashflow-1103.9%-229,031-19,02452,81978,781-213,245101,396-39,344-57,200-80,414-45,321-64,346-92,968-59,967-34,81713,011-37,418-
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Assets-46.2%5711,0601,2581,4548091,5582,0632,6809519521,216867267829829583337
  Current Assets-53.3%4289161,1291,2746251,4601,8612,4917535597188091901.001.00-253
    Cash Equivalents-41.0%17629931019110438332427430020248640592.0090.0010711268.00
  Net PPE11.2%5.005.005.005.006.003.002.002.002.002.002.002.002.00---2.00
Liabilities-61.5%2847389271,1304521,1661,6362,19041154090127843331.0029.00-378
  Current Liabilities-63.7%2617199081,1104321,1281,5992,1523722301961731642.000.001.00142
  Long Term Debt------20.0020.0020.0020.0020.0020.005.00106---58.00
    LT Debt, Non Current------20.0020.0020.0020.0020.0020.0024.00106---58.00
Shareholder's Equity-11.0%2863223313233573924274905404123155895.005.005.000.00-
  Retained Earnings-3.4%-2,159-2,089-2,047-2,019-1,946-1,871-1,796-1,692-1,616-1,429-1,395-1,077-1,028-2.37-0.07-0.02-891
  Additional Paid-In Capital1.4%2,4612,4282,3952,3592,3192,2812,2382,1952,1541,8391,7061,6634127.005.000.00403
Shares Outstanding-100.0%-481-47947647647547341341539537689.0089.0089.0088.0088.00
Minority Interest---------4.004.004.004.004.00----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-1120.9%-229,295-18,78153,17379,032-209,368101,655-39,171-57,042-80,176-45,126-64,155-92,869-59,904-34,65013,232-37,176-17.63
  Share Based Compensation0.2%33,13633,07036,10838,61739,09442,64441,92740,64031,18146,80343,02642,7132,1291,5011,4711,977-
Cashflow From Investing511.7%83,662-20,32166,49110,18112,656-43,38989,35336,513-106,491-242,345170,865-257,47667,5571,500-14,16382,510-
Cashflow From Financing-1408.8%-29,617-1,963-147-2,13456.00132458-5,608284,3713,988-25,470662,504-5,03715,470-4,151-43818.00
  Buy Backs-58.5%8271,9944172,98242.002761055,939-147-------

CLOV Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Premiums earned, net (Net of ceded premiums of $444, $470, and $489 for the years ended December 31, 2023 and 2022, and 2021 respectively)$ 1,235,769,000$ 1,084,869,000$ 799,414,000
Non-Insurance revenue773,177,0002,380,135,000667,639,000
Other income24,774,00011,683,0004,943,000
Total revenues2,033,720,0003,476,687,0001,471,996,000
Operating expenses:   
Net medical claims incurred1,776,388,0003,453,952,0001,551,178,000
Salaries and benefits257,157,000278,725,000260,458,000
General and administrative expenses187,571,000207,917,000185,287,000
Impairment of goodwill and other intangible assets15,945,00000
Premium deficiency reserve expense (benefit)(7,239,000)(93,517,000)110,628,000
Depreciation and amortization2,509,0001,187,0001,246,000
Restructuring costs9,931,00000
Other expense070,000191,000
Total operating expenses2,242,262,0003,848,334,0002,108,988,000
Income (loss) from operations(208,542,000)(371,647,000)(636,992,000)
Change in fair value of warrants86,000(900,000)(66,146,000)
Interest expense7,0001,333,0003,193,000
Amortization of notes and securities discounts030,00013,717,000
Loss (gain) on investment4,726,000(9,217,000)0
Gain on extinguishment of note payable0(23,326,000)0
Net loss$ (213,361,000)$ (339,567,000)$ (587,756,000)
Per share data:   
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share)[1]$ (0.44)$ (0.71)$ (1.42)
Net loss per share attributable to Class A and Class B common stockholders - diluted (in dollars per share)[1]$ (0.44)$ (0.71)$ (1.42)
Weighted average number of common shares outstanding   
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)[1]482,176,127476,244,262412,922,424
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)[1]482,176,127476,244,262412,922,424
Net unrealized gain (loss) on available-for-sale investments$ 7,004,000$ (7,440,000)$ (1,944,000)
Comprehensive loss$ (206,357,000)$ (347,007,000)$ (589,700,000)
[1]
(1) Because the Company had a Net loss during the years ended December 31, 2023, 2022, and 2021, the Company's potentially dilutive securities, which include stock options, restricted stock units, preferred stock, and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.

CLOV Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 122,863$ 103,791
Short-term investments12,21841,457
Investment securities, available-for-sale (Amortized cost: 2023: $101,412; 2022: $193,300)100,702189,498
Investment securities, held-to-maturity (Fair value: 2023: $6,778; 2022: $15)6,90215
Accrued retrospective premiums22,07620,387
Other receivables16,66623,596
Healthcare receivables64,16470,607
Non-Insurance receivable10,92652,955
Surety bonds and deposits55,631100,502
Prepaid expenses14,41818,146
Other assets, current1,4044,043
Total current assets427,970624,997
Investment securities, available-for-sale (Amortized cost: 2023: $121,868; 2022: $142,940)120,208137,368
Investment securities, held-to-maturity (Fair value: 2023: $692; 2022: $636)793742
Property and equipment, net5,0825,753
Operating lease right-of-use assets3,3824,025
Goodwill and other intangible assets2,99020,000
Other assets, non-current10,24615,735
Total assets570,671808,620
Current liabilities  
Unpaid claims138,593141,947
Non-Insurance performance year obligation, current15,56873,844
Non-Insurance payable41,565148,191
Accounts payable and accrued expenses37,18432,445
Accrued salaries and benefits21,06123,962
Deferred revenue3,0990
Operating lease liabilities1,6651,827
Premium deficiency reserve07,239
Total current liabilities261,115431,507
Long-term operating lease liabilities2,9984,033
Other liabilities, non-current20,16416,193
Total liabilities284,277451,733
Commitments and Contingencies (Note 19)
Stockholders' equity  
Additional paid-in capital2,461,2382,319,157
Accumulated other comprehensive loss(2,370)(9,374)
Accumulated deficit(2,159,794)(1,946,433)
Less: Treasury stock, at cost; 7,912,750 and 2,072,752 shares held at December 31, 2023 and December 31, 2022, respectively(12,729)(6,509)
Total stockholders' equity286,394356,887
Total liabilities and stockholders' equity570,671808,620
Common Class A  
Stockholders' equity  
Common stock, value4037
Common Class B  
Stockholders' equity  
Common stock, value99
Related party  
Current liabilities  
Due to related parties, net1,3631,566
Other liabilities, current1,3631,566
Nonrelated Party  
Current liabilities  
Due to related parties, net1,017486
Other liabilities, current$ 1,017$ 486
CLOV
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. The company was incorporated in 2014 and is based in Franklin, Tennessee.
 CEO
 WEBSITEwww.cloverhealth.com
 EMPLOYEES656

Clover Health Investments, Corp. Frequently Asked Questions


What is the ticker symbol for Clover Health Investments, Corp.? What does CLOV stand for in stocks?

CLOV is the stock ticker symbol of Clover Health Investments, Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Clover Health Investments, Corp. (CLOV)?

As of Wed Mar 27 2024, market cap of Clover Health Investments, Corp. is 379.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLOV stock?

You can check CLOV's fair value in chart for subscribers.

What is the fair value of CLOV stock?

You can check CLOV's fair value in chart for subscribers. The fair value of Clover Health Investments, Corp. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Clover Health Investments, Corp. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLOV so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Clover Health Investments, Corp. a good stock to buy?

The fair value guage provides a quick view whether CLOV is over valued or under valued. Whether Clover Health Investments, Corp. is cheap or expensive depends on the assumptions which impact Clover Health Investments, Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLOV.

What is Clover Health Investments, Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CLOV's PE ratio (Price to Earnings) is -1.78 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLOV PE ratio will change depending on the future growth rate expectations of investors.